Title	Publication Date	Language	Citations
A report from the European association for the study of the Liver's 50th international liver congress (April 22-26 - Vienna, Austria)	2015/01/01
2012 in review - Part II: Overcoming the obstacles in the pharma/biotech industry	2013/01/01
New product intros (almonertinib, bempedoic acid (first-in-class), cetirizine hydrochloride (new formulation), calaspargase pegol-mknl, eptinezumab-jjmr, lumateperone tosylate, luspatercept (new indication), remimazolam tosylate, teprotumumab-trbw)	2020/01/01
New product intros (alpelisib, anlotinib hydrochloride (new indication), apremilast (new indication), camrelizumab, peficitinib hydrobromide, polatuzumab vedotin-piiq (first-in-class), remogliflozin etabonate, solriamfetol hydrochloride)	2019/01/01
New product intros (anlotinib dihydrochloride, brexanolone, dexamethasone punctum plug (new formulation), dupilumab (new indication), eculizumab (new indication), halobetasol propionate/tazarotene (new combination), selinexor)	2019/01/01
New product intros (dolutegravir sodium/lamivudine (new combination), esaxerenone, onasemnogene abeparvovec-xioi, padeliporfin potassium, risankizumab, ruxolitinib phosphate (new indication))	2019/01/01
New product intros (bremelanotide acetate (first-in-class), budesonide/glycopyrronium bromide/formoterol fumarate (new combination), darolutamide, entrectinib, erdafitinib (first-in-class), glucagon (intranasal), ixekizumab (new indication), pexidartinib hydrochloride, tapinarof, tree pollen sublingual immunotherapy (SLIT) tablet allergy vaccine, upadacitinib tartrate, volanesorsen)	2019/01/01
New product intros (emapalumab-lzsg, lamivudine/tenofovir disoproxil fumarate (new combination), levodopa (new formulation), relugolix, romosozumab, sintilimab, sodium zirconium cyclosilicate)	2019/01/01
New product intros (binimetinib, encorafenib, incobotulinumtoxin A (new indication), Japanese cedar tree pollen allergy vaccine)	2018/01/01
The 9th Annual Biosimilar Asia 2018 (May 16-17, 2018 - Shanghai, China)	2018/01/01
LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors	2019/01/01
New product intros (17beta-estradiol/progesterone (new combination), mirogabalin besylate, netarsudil mesylate/latanoprost (new combination), RTS,S/AS01, siponimod fumarate, tafenoquine succinate (new indication))	2019/01/01
BIO-Europe Spring 2019 - 13th Annual International Partnering Conference (March 25-27, 2019 - Vienna, Austria)	2019/01/01
New product intros (dacomitinib, elapegademase-lvlr, glasdegib maleate, revefenacin, talazoparib tosylate)	2019/01/01
New product intros (betibeglogene darolentivec, evocalcet (new indication), fexinidazole, GV-971, lascufloxacin hydrochloride, luspatercept-aamt, semaglutide (new formulation), trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki), voxelotor)	2020/01/01
New product intros (Ad5-EBOV; cannabidiol; dupilumab (new indication); eravacycline; galcanezumab-gnlm; glycopyrrolate tosylate; influenza vaccine, quadrivalent; lanadelumab-flyo; tildrakizumab-asmn)	2018/01/01
Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A	2018/01/01
Apalutamide for the treatment of patients with castration-resistant prostate cancer	2018/01/01
Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia	2018/01/01
New product intros (albuvirtide, anakinra (new indication), cemiplimab-rwlc, damoctocog alfa pegol, doravirine, doravirine/lamivudine/tenofovir disoproxil fumarate (new combination), duvelisib, pyrotinib maleate, tafenoquine succinate, testosterone gel (new formulation)	2018/01/01
Life sciences licensing deals in the second quarter of 2018: updates and trends	2018/01/01
New product intros (danoprevir, fosravuconazole L-lysine ethanolate, ivosidenib, plazomicin)	2018/01/01
An update of lanreotide acetate for treatment of adults with carcinoid syndrome	2018/01/01
Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary)	2018/01/01
Loncastuximab tesirine for diffuse large B-cell lymphoma	2021/01/01
New product intros (amivantamab-vmjw, anifrolumab-fnia (first-in-class), asciminib, atogepant, avalglucosidase alfa-ngpt, bimekizumab, clascoterone, donafenib, lonapegsomatropin-tcgd, mobocertinib, samidorphan/olanzapine (new combination), teserpaturev, tisotumab vedotin (first-in-class), vosoritide)	2021/01/01
American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)	2021/01/01
MedTech Forum 2021 (April 20-22, 2021 - Virtual Meeting)	2021/01/01
New product intros (anamorelin hydrochloride, casimersen, loncastuximab tesirine, dapagliflozin (new indication), molidustat sodium, mometasone furoate/azelastine hydrochloride (new combination), OTL-200, setmelanotide, umbralisib tosylate (first-in-class), vericiguat)	2021/01/01
New product intros (aducanumab-avwa, aviptadil, belumosudil mesylate, belzutifan (first-in-class), disitamab vedotin, dostarlimab-gxly, fuzuloparib, hetrombopag olamine, ibrexafungerp, imeglimin hydrochloride (first-in-class), infigratinib, Kconvac)	2021/01/01